Diagnostics company Genetic Signaturesâ (ASX:GSS) EasyScreen Gastrointestinal Parasite Detection Kit and GS1 automated workflow secured Food & Drug Administration clearance for marketing and sale in the US, according to a Tuesday filing with the Australian Securities Exchange.
The company has installed instruments and completed training at nine sites, including hospitals, health departments and corporate pathology providers, under a customer experience program in preparation for the kitâs commercial launch, the filing said.
Once a properly packed and labeled product is available and the company's pathology provider customers have finished their internal technological evaluation and approval procedure, the first commercial sale is expected to occur within 60 to 90 days of clearance, according to the filing.
Price (AUD): $0.73, Change: $, Percent Change: %
Comments